Developer docs
API playgroundTry for free, no card

Search company profiles

Cyanvac

Full company profile

uuid000dmfr

Namestring
Cyanvac
Legal namestring
CyanVac LLC
Websiteurl
cyanvacllc.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

CyanVac LLC is a privately held, clinical-stage biotechnology company founded in 2017 and headquartered in Athens, Georgia. The company develops intranasal vaccines built on a proprietary parainfluenza virus 5 (PIV5)-based vector platform invented by CEO Dr. Biao He. The platform is designed to deliver needle-free, single-dose vaccines that generate cellular, humoral, and mucosal immunity, with PIV5 having an established 50+ year safety record from its use in canine distemper vaccines.

Cyanvac's pipeline comprises five programs leveraging this shared backbone: CVXGA (intranasal COVID-19 vaccine, with completed Phase 1 NCT04954287 and Phase 2 NCT05736835 studies); BLB201 (intranasal RSV vaccine expressing native full-length F-protein, granted FDA Fast Track designation and in a Phase 1/2 pediatric trial NCT05655182, developed through wholly-owned affiliate Blue Lake Biotechnology); pandemic avian flu vaccines targeting H5N1 and H7N9; a norovirus candidate; and a Lyme disease candidate. Manufacturing economics are positioned as a differentiator, with the company stating a 300-liter bioreactor can produce millions of doses per month versus the 10,000s of liters required for other virus-based vaccine platforms.

The company is pre-revenue and distributes its candidates only through clinical trials. Commercialization is expected to follow traditional pharmaceutical channels post-approval, with a particular go-to-market emphasis on needle-hesitant populations, pediatric and elderly RSV segments, and government pandemic-procurement pathways. Operations appear to be supported primarily by founder/management capital and academic ties to the University of Georgia, with no disclosed venture or institutional funding rounds.

Short descriptiontext

CyanVac LLC is a privately held, clinical-stage biotechnology company developing needle-free intranasal vaccines on a proprietary PIV5-based vector platform, with a pipeline spanning COVID-19, RSV, avian flu, norovirus, and Lyme disease. It serves clinical trial participants today and targets broad global vaccine markets post-approval.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAthens, United States
HQ citystring
Athens
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
intranasal vaccines, vaccine development, viral vector platform, infectious disease vaccines, biopharmaceutical research
Industry4 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAF
Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAB
Adult Vaccines
SECONDARYHLAIAEAD
Seasonal & Endemic Vaccines (e.g., Influenza)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Vaccines
Social media profiles1 record
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cyanvac develops intranasal vaccines using a proprietary parainfluenza virus 5 (PIV5)-based vector platform invented by CEO Dr. Biao He. The company's clinical pipeline includes CVXGA (intranasal COVID-19 vaccine with completed Phase 1 and Phase 2 studies), BLB201 (RSV vaccine developed by affiliate Blue Lake Biotechnology with FDA Fast Track designation), and preclinical candidates targeting avian flu (H5N1/H7N9), norovirus, and Lyme disease. All vaccine candidates leverage the PIV5 vector to generate cellular, humoral, and mucosal immunity with needle-free intranasal delivery and scalable manufacturing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • PIV5-based vaccines protect against approximately 15 different pathogens in multiple animal species including mice, guinea pigs, hamsters, ferrets, cats, pigs, and monkeys
+5 more records
Product overview1 text field

CyanVac is developing intranasal vaccines using its proprietary PIV5-based platform technology. The company's pipeline includes CVXGA (intranasal COVID-19 vaccine with completed Phase 1 and Phase 2 studies), BLB201 (RSV vaccine developed by affiliate Blue Lake Biotechnology with FDA Fast Track designation), and preclinical vaccines for pandemic avian flu (H5N1/H7N9), norovirus, and Lyme disease. All vaccines leverage the PIV5 vector system to generate robust cellular, humoral, and mucosal immunity with needle-free intranasal delivery.

Product and service6 records
1PIV5-Based Vaccine Platform
CategoryVaccine Technology Platform
Description

A proprietary parainfluenza virus 5 (PIV5)-based vector system for developing intranasal vaccines that can be easily delivered worldwide. The platform generates robust cellular, humoral, and mucosal immune responses, with potential single-dose efficacy and scalable manufacturing using small bioreactors.

2CVXGA
CategoryCOVID-19 Vaccine
Description

Intranasal COVID-19 vaccine designed to produce mucosal immunity, reduce transmission, address needle hesitancy, and serve as a booster for previously vaccinated or infected individuals. Phase 1 (NCT04954287) and Phase 2 (NCT05736835) studies completed.

3BLB201
CategoryRSV Vaccine
Description

Live intranasal RSV vaccine expressing native full-length F-protein, developed by affiliate Blue Lake Biotechnology. Granted FDA Fast Track designation. Phase 1 study completed in adults (NCT05281263); Phase 1/2 study in children in progress (NCT05655182).

4Pandemic (Avian) Flu Vaccines
CategoryPandemic Influenza Vaccine
Description

PIV5-based intranasal vaccines protecting against H5N1 and H7N9 avian flu viruses. Designed to generate mucosal immunity that could reduce person-to-person transmission and enable self-administration at home during pandemic scenarios.

5Norovirus Vaccine
CategoryNorovirus Vaccine
Description

Vaccine candidate targeting norovirus, the most common cause of acute gastroenteritis worldwide. Addresses approximately 20 million annual US infections, 465,000 ER visits, 190,000 hospitalizations, and 900 deaths.

6Lyme Disease Vaccine
CategoryLyme Disease Vaccine
Description

Vaccine candidate targeting Lyme disease caused by Borrelia burgdorferi, transmitted by Ixodes ticks. Addresses the most common vector-borne disease in the US with approximately 476,000 annual diagnoses and up to 30% of patients developing post-treatment Lyme disease syndrome.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CyanVac's wholly-owned affiliate developing the RSV vaccine BLB201 on the same proprietary PIV5-based intranasal platform. It is the closest comparability match — same founder, same technology backbone, same regulatory pathway — but focuses specifically on the BLB201 RSV program while CyanVac holds the broader pipeline.

TypeDirect peer
Description

Clinical-stage biotech developing needle-free oral tablet vaccine candidates (including COVID and norovirus) using an adenovirus-based vector platform. Direct strategic peer in the "non-injectable respiratory/GI vaccine" niche, with analogous clinical-stage milestones and platform-vs-single-product debate.

TypeDirect peer
Description

Develops intranasal vaccines (including AdCOVID for COVID-19 and T-COVID for intranasal immune modulation) using an adenovirus-based platform. Direct comparability match on the intranasal vaccine delivery mechanism and respiratory pathogen targets (COVID, RSV, influenza).

TypeDirect peer
Description

Clinical-stage developer of intranasal live-attenuated influenza vaccines (M2SR) targeting improved efficacy over traditional flu shots. Direct intranasal vaccine peer with single-disease focus that overlaps on the mucosal immunity and intranasal delivery thesis.

TypeDirect peer
Description

Clinical-stage biotech developing intranasal live-attenuated RSV vaccines (MVs RSV), competing head-to-head with CyanVac-affiliate Blue Lake Biotechnology's BLB201. Direct peer on pediatric RSV intranasal approach with similar small-team, clinical-stage profile.

TypeDirect peer
Description

Develops intranasal live-attenuated vaccines using codon-deoptimization technology, with preclinical and clinical programs in RSV, influenza, and COVID-19. Direct comparison on the platform-based intranasal vaccine thesis and small-biotech-to-Big-Pharma partnership model.

TypeEmerging player
Description

Approved an intranasal adenovirus-vectored COVID-19 vaccine (Convidecia Air) and is developing inhaled tuberculosis and other mucosal vaccines. Most commercially advanced intranasal vaccine peer, providing regulatory and manufacturing precedents for the delivery route.

TypeEmerging player
Description

Developed and markets iNCOVACC, an second-generation intranasal adenoviral COVID-19 vaccine, and is developing intranasal rotavirus, cholera, and typhoid vaccines. Comparable as an intranasal vaccine developer in global public health markets.

9MedImmune / AstraZeneca
TypeBroad incumbent
Description

Inventor and long-time marketer of FluMist, the first commercially successful intranasal influenza vaccine, and a major Big-Pharma vaccine player whose RSV program (nirsevimab via Beyfortus partnership) competes in the same indications as CyanVac. Reference incumbent for intranasal vaccine regulatory pathway and commercial benchmarks.

TypeBroad incumbent
Description

Dominant mRNA vaccine developer with approved COVID-19 (Spikevax) and RSV (mRESVIA) vaccines plus influenza programs. Incumbent competitor across CyanVac's lead respiratory disease targets, with vastly larger commercial reach but a delivery mechanism that does not generate mucosal immunity.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cyanvac

Biopharmaceutical Vaccinescyanvacllc.com

CyanVac LLC is a privately held, clinical-stage biotechnology company developing needle-free intranasal vaccines on a proprietary PIV5-based vector platform, with a pipeline spanning COVID-19, RSV, avian flu, norovirus, and Lyme disease. It serves clinical trial participants today and targets broad global vaccine markets post-approval.

What Cyanvac does

CyanVac LLC is a privately held, clinical-stage biotechnology company founded in 2017 and headquartered in Athens, Georgia. The company develops intranasal vaccines built on a proprietary parainfluenza virus 5 (PIV5)-based vector platform invented by CEO Dr. Biao He. The platform is designed to deliver needle-free, single-dose vaccines that generate cellular, humoral, and mucosal immunity, with PIV5 having an established 50+ year safety record from its use in canine distemper vaccines.

Cyanvac's pipeline comprises five programs leveraging this shared backbone: CVXGA (intranasal COVID-19 vaccine, with completed Phase 1 NCT04954287 and Phase 2 NCT05736835 studies); BLB201 (intranasal RSV vaccine expressing native full-length F-protein, granted FDA Fast Track designation and in a Phase 1/2 pediatric trial NCT05655182, developed through wholly-owned affiliate Blue Lake Biotechnology); pandemic avian flu vaccines targeting H5N1 and H7N9; a norovirus candidate; and a Lyme disease candidate. Manufacturing economics are positioned as a differentiator, with the company stating a 300-liter bioreactor can produce millions of doses per month versus the 10,000s of liters required for other virus-based vaccine platforms.

The company is pre-revenue and distributes its candidates only through clinical trials. Commercialization is expected to follow traditional pharmaceutical channels post-approval, with a particular go-to-market emphasis on needle-hesitant populations, pediatric and elderly RSV segments, and government pandemic-procurement pathways. Operations appear to be supported primarily by founder/management capital and academic ties to the University of Georgia, with no disclosed venture or institutional funding rounds.

Cyanvac firmographics

Firmographics
Name
Cyanvac
Legal name
CyanVac LLC
Website
https://cyanvacllc.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
CyanVac LLC is a privately held, clinical-stage biotechnology company developing needle-free intranasal vaccines on a proprietary PIV5-based vector platform, with a pipeline spanning COVID-19, RSV, avian flu, norovirus, and Lyme disease. It serves clinical trial participants today and targets broad global vaccine markets post-approval.
Ownership category
akta.pro rank

Cyanvac industry classification

Industry
Product category
Biopharmaceutical Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAF
Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAB
Adult Vaccines
SECONDARYHLAIAEAD
Seasonal & Endemic Vaccines (e.g., Influenza)

Keywords

  • Intranasal vaccines
  • Vaccine development
  • Viral vector platform
  • Infectious disease vaccines
  • Biopharmaceutical research

Where Cyanvac is headquartered

Location

Headquarters

HQ city
Athens
HQ country
United States
HQ region
North America

Markets served

Cyanvac business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain

Distribution channels2 records

Marketing channels3 records

Cyanvac product offering

Product offering

Core offering

Cyanvac develops intranasal vaccines using a proprietary parainfluenza virus 5 (PIV5)-based vector platform invented by CEO Dr. Biao He. The company's clinical pipeline includes CVXGA (intranasal COVID-19 vaccine with completed Phase 1 and Phase 2 studies), BLB201 (RSV vaccine developed by affiliate Blue Lake Biotechnology with FDA Fast Track designation), and preclinical candidates targeting avian flu (H5N1/H7N9), norovirus, and Lyme disease. All vaccine candidates leverage the PIV5 vector to generate cellular, humoral, and mucosal immunity with needle-free intranasal delivery and scalable manufacturing.

Product overview

CyanVac is developing intranasal vaccines using its proprietary PIV5-based platform technology. The company's pipeline includes CVXGA (intranasal COVID-19 vaccine with completed Phase 1 and Phase 2 studies), BLB201 (RSV vaccine developed by affiliate Blue Lake Biotechnology with FDA Fast Track designation), and preclinical vaccines for pandemic avian flu (H5N1/H7N9), norovirus, and Lyme disease. All vaccines leverage the PIV5 vector system to generate robust cellular, humoral, and mucosal immunity with needle-free intranasal delivery.

Differentiator

Problem solved

Functional benefit

Products and services

  • PIV5-Based Vaccine Platform A proprietary parainfluenza virus 5 (PIV5)-based vector system for developing intranasal vaccines that can be easily delivered worldwide. The platform generates robust cellular, humoral, and mucosal immune responses, with potential single-dose efficacy and scalable manufacturing using small bioreactors.
  • CVXGA Intranasal COVID-19 vaccine designed to produce mucosal immunity, reduce transmission, address needle hesitancy, and serve as a booster for previously vaccinated or infected individuals. Phase 1 (NCT04954287) and Phase 2 (NCT05736835) studies completed.
  • BLB201 Live intranasal RSV vaccine expressing native full-length F-protein, developed by affiliate Blue Lake Biotechnology. Granted FDA Fast Track designation. Phase 1 study completed in adults (NCT05281263); Phase 1/2 study in children in progress (NCT05655182).
  • Pandemic (Avian) Flu Vaccines PIV5-based intranasal vaccines protecting against H5N1 and H7N9 avian flu viruses. Designed to generate mucosal immunity that could reduce person-to-person transmission and enable self-administration at home during pandemic scenarios.
  • Norovirus Vaccine Vaccine candidate targeting norovirus, the most common cause of acute gastroenteritis worldwide. Addresses approximately 20 million annual US infections, 465,000 ER visits, 190,000 hospitalizations, and 900 deaths.
  • Lyme Disease Vaccine Vaccine candidate targeting Lyme disease caused by Borrelia burgdorferi, transmitted by Ixodes ticks. Addresses the most common vector-borne disease in the US with approximately 476,000 annual diagnoses and up to 30% of patients developing post-treatment Lyme disease syndrome.

Quantifiable outcome

  • PIV5-based vaccines protect against approximately 15 different pathogens in multiple animal species including mice, guinea pigs, hamsters, ferrets, cats, pigs, and monkeys
  • +5 more outcomes

Companies that use Cyanvac

Customer profile

Segments5 records

Ideal customer profiles3 records

Cyanvac technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Cyanvac partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights6 records

Cyanvac competitors and assessment

Company assessment

Direct peers

  • Blue Lake Biotechnology: CyanVac's wholly-owned affiliate developing the RSV vaccine BLB201 on the same proprietary PIV5-based intranasal platform. It is the closest comparability match — same founder, same technology backbone, same regulatory pathway — but focuses specifically on the BLB201 RSV program while CyanVac holds the broader pipeline.
  • Vaxart: Clinical-stage biotech developing needle-free oral tablet vaccine candidates (including COVID and norovirus) using an adenovirus-based vector platform. Direct strategic peer in the "non-injectable respiratory/GI vaccine" niche, with analogous clinical-stage milestones and platform-vs-single-product debate.
  • Altimmune: Develops intranasal vaccines (including AdCOVID for COVID-19 and T-COVID for intranasal immune modulation) using an adenovirus-based platform. Direct comparability match on the intranasal vaccine delivery mechanism and respiratory pathogen targets (COVID, RSV, influenza).
  • FluGen: Clinical-stage developer of intranasal live-attenuated influenza vaccines (M2SR) targeting improved efficacy over traditional flu shots. Direct intranasal vaccine peer with single-disease focus that overlaps on the mucosal immunity and intranasal delivery thesis.
  • Meissa Vaccines: Clinical-stage biotech developing intranasal live-attenuated RSV vaccines (MVs RSV), competing head-to-head with CyanVac-affiliate Blue Lake Biotechnology's BLB201. Direct peer on pediatric RSV intranasal approach with similar small-team, clinical-stage profile.
  • Codagenix: Develops intranasal live-attenuated vaccines using codon-deoptimization technology, with preclinical and clinical programs in RSV, influenza, and COVID-19. Direct comparison on the platform-based intranasal vaccine thesis and small-biotech-to-Big-Pharma partnership model.

Emerging players

  • CanSino Biologics: Approved an intranasal adenovirus-vectored COVID-19 vaccine (Convidecia Air) and is developing inhaled tuberculosis and other mucosal vaccines. Most commercially advanced intranasal vaccine peer, providing regulatory and manufacturing precedents for the delivery route.
  • Bharat Biotech: Developed and markets iNCOVACC, an second-generation intranasal adenoviral COVID-19 vaccine, and is developing intranasal rotavirus, cholera, and typhoid vaccines. Comparable as an intranasal vaccine developer in global public health markets.

Broad incumbents

  • MedImmune / AstraZeneca: Inventor and long-time marketer of FluMist, the first commercially successful intranasal influenza vaccine, and a major Big-Pharma vaccine player whose RSV program (nirsevimab via Beyfortus partnership) competes in the same indications as CyanVac. Reference incumbent for intranasal vaccine regulatory pathway and commercial benchmarks.
  • Moderna: Dominant mRNA vaccine developer with approved COVID-19 (Spikevax) and RSV (mRESVIA) vaccines plus influenza programs. Incumbent competitor across CyanVac's lead respiratory disease targets, with vastly larger commercial reach but a delivery mechanism that does not generate mucosal immunity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Cyanvac social profiles

Digital presence

Cyanvac financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cyanvac leadership team

Management profile

Number of profiles

Profiles8 records

Cyanvac subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Cyanvac funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cyanvac M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cyanvac

What does Cyanvac do?

Cyanvac develops intranasal vaccines using a proprietary parainfluenza virus 5 (PIV5)-based vector platform invented by CEO Dr. Biao He. The company's clinical pipeline includes CVXGA (intranasal COVID-19 vaccine with completed Phase 1 and Phase 2 studies), BLB201 (RSV vaccine developed by affiliate Blue Lake Biotechnology with FDA Fast Track designation), and preclinical candidates targeting avian flu (H5N1/H7N9), norovirus, and Lyme disease. All vaccine candidates leverage the PIV5 vector to generate cellular, humoral, and mucosal immunity with needle-free intranasal delivery and scalable manufacturing.

Is Cyanvac a public or private company?

Cyanvac is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Cyanvac founded?

Cyanvac was founded in 2017. It employs 11 to 50 people.

Where is Cyanvac based?

Cyanvac is headquartered in Athens, United States, in the North America region.

Who are Cyanvac's main competitors?

Direct peers on record are Blue Lake Biotechnology, Vaxart, Altimmune, FluGen, Meissa Vaccines and Codagenix. Emerging players are CanSino Biologics and Bharat Biotech. Broad incumbents are MedImmune / AstraZeneca and Moderna.

Does Cyanvac have an API?

No public API is recorded for Cyanvac.

What industry is Cyanvac in?

Cyanvac's product category is Biopharmaceutical Vaccines. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAF, Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ReutersUS government to fund up to $500 mln for studies on oral, nasal COVID vaccinesThe U.S. Department of Health and Human Services announced up to $500 million for mid-stage trials of oral and nasal COVID vaccines. BARDA awarded $453 million to Vaxart for its oral vaccine and about $34 million to Castlevax and $40 million to Cyanvac for intranasal candidates. Each trial will enroll 10,000 volunteers.PR NewswireCyanVac CEO Speaks at White House Summit on the Future of COVID-19 VaccinesCyanVac LLC founder and CEO Dr. Biao He participated as a panelist at the White House Summit on the Future of COVID-19 Vaccines on July 26, 2022, discussing intranasal vaccines that generate mucosal immunity to potentially block SARS-CoV-2 transmission. The company is currently conducting Phase 1 clinical trials for its COVID-19 vaccine candidate CVXGA1, while its subsidiary Blue Lake Biotechnology is separately conducting Phase 1 trials for an RSV vaccine candidate BLB-201. Preclinical data published in Science Advances showed the CVXGA1 vaccine reduced SARS-CoV-2 transmission between animals in a ferret model.PR NewswireCyanVac and Blue Lake Biotechnology Announce FDA Clearance of IND Application for BLB-201 Intranasal RSV VaccineCyanVac LLC and its subsidiary Blue Lake Biotechnology have received FDA clearance for their investigational new drug application for BLB-201, an intranasal vaccine candidate for respiratory syncytial virus, enabling the companies to advance into Phase 1 clinical trials. The vaccine leverages a proprietary PIV5-based vector platform and is designed for single-dose intranasal administration without injection. The trial will evaluate safety and immunogenicity in adults aged 18-75 at Cincinnati Children's Hospital Medical Center, with the goal of addressing RSV prevention for which no approved vaccine currently exists.